Login to Your Account

Gilead captures approval for pan-genotypic HCV therapy

By Michael Fitzhugh
Staff Writer

Tuesday, June 28, 2016

Gilead Sciences Inc. landed an on-schedule FDA approval for the chronic HCV drug Epclusa, the first drug effective against all six major genotypes of the virus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription